Twist Bioscience Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Well, we're happy to be hosting Twist Biopharma Biosciences here on our next panel. From Twist, we have Jim Thorburn, who is CFO; and Patrick Finn, Chief Commercial Officer. Welcome.
Gregg. And this is Patrick, we're both Scottish. So there will be a translator.
And also, I'd like to mention there's instructions on the screen there and on the table. If you have a question in the audience, you can go ahead and ask them and we can read them here off the iPad.
Questions & Answers
But maybe just kind of starting off, Twist just reported its fiscal third quarter and raised revenue guidance during the quarter. Can you maybe talk a little bit on the puts and takes that you're seeing there and what drove the revenue guidance?
Yes. So revenue guidance this year is a bit, say, $130 million, actually
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |